EGFR and cancer: Despite advances in understanding HNC biology (EGFR overexpression and p53 mutation), and the evolution of therapeutic strategies (chemoradiation treatment, targeted therapy, and immunotherapy) [3,4,5], these cancers often exhibit radioresistance, leading to treatment failure and poor prognoses.